DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule (DISCERN-FN7)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: François Dubos, MD,PhD
- Phone Number: +33 (3) 20 44 59 20
- Email: francois.dubos@chru-lille.fr
Study Locations
-
-
-
Lille, France, 59037
- Hop Jeanne de Flandre Chu Lille
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Followed for hemopathy or cancer,
- Presenting with post-chemotherapy NF,
- With social security coverage,
- With parents able to provide appropriate home supervision,
- Consent of parents and child if able to give consent.
Exclusion Criteria:
- NF to diagnosis of tumor disease,
- Child with palliative care,
- Child who has had an allogeneic hematopoietic stem cell transplant within the past year,
- NF immediately following an autologous hematopoietic stem cell transplant,
- Participation in the study during a previous NF,
- Curative antibiotic therapy or documented infection prior to admission,
- Initial management at a non-investigative center,
- Refusal of the child or parents to participate
Translated with www.DeepL.com/Translator (free version)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: management reduction strategy
Patients classified as low risk by the DRC who will have a reduction in the management of their post-chemotherapy NF.
|
The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer.
Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief.
Treatment reduction for the experimental group was started immediately after randomization, in hospital.
Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
|
|
Active Comparator: standard management
Patients classified as low risk by the DRC who will have standard management of post-chemotherapy NF.
|
The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer.
Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief.
Treatment reduction for the experimental group was started immediately after randomization, in hospital.
Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in quality of life score, calculated from the PedsQL™ scale between inclusion and Day 6.
Time Frame: at day 6
|
The Pediatric Quality of Life Inventory (PedsQL) is a brief measure of health-related quality of life in children and young people. The measure can be completed by parents (the Proxy Report) as well as children and young people (the Self-Report). On the PedsQL Generic Core Scales, for ease of interpretability, items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life). To reverse score, transform the 0-4 scale items to 0-100 as follows: 0=100, 1=75, 2=50, 3=25, 4=0. |
at day 6
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: François Dubos, MD,PhD, University Hospital, Lille
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018_99
- 2019-A01025-52 (Other Identifier: ID-RCB number,ANSM)
- PREPS-18-0507 (Other Identifier: DGOS number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.